Two Revenue Leaks. Most Healthcare Publishers Haven't Named Either.
Healthcare publishing has been under pressure for years. But the conversations happening in boardrooms and planning meetings tend to orbit the same broad explanation: AI is disrupting search, traffic is down, programmatic revenue is compressing. The diagnosis stops there.
That level of analysis does not help a publisher fix anything.
What helps is getting specific naming the exact mechanisms that are eroding revenue, and understanding how each one compounds the others. Two of them, in particular, are responsible for more damage than most publishers have formally accounted for.
Leak 1: You're Selling Inventory Built on Bot Data
Approximately 50% of all web traffic today is non-human. That is not a fringe statistic, it is a structural feature of the current web. Of that non-human traffic, 32% comes from bots that are not indexing content for search. They are scraping it: extracting clinical articles, drug reference information, CME modules, and physician education content at scale, programmatically and persistently.
For healthcare publishers, this has a specific and under-discussed consequence on advertising.
Ad inventory is priced and sold on impressions and engagement data. If a meaningful portion of the traffic generating those impressions is non-human, the CPMs being negotiated are benchmarked against inflated numbers. Advertisers particularly pharmaceutical and life sciences brands with increasingly sophisticated media measurement, will eventually reconcile their campaign performance against actual HCP reach. When they do, the gap between promised and delivered audience becomes a CPM and contract renegotiation problem.
The inventory quality issue and the content scraping issue are the same event, viewed from two different seats. The bot that scrapes a publisher's clinical article contributes a non-human session to the analytics dashboard while simultaneously using that content to fuel AI systems that will answer the next physician's clinical query without sending them to the publisher's site at all.
Publishers are funding both problems simultaneously: paying to create and host content that is being taken without compensation and then reporting ad performance against the non-human engagement that same extraction generates.
Leak 2: CME Revenue Is Moving Off Your Platform
Continuing Medical Education is one of the highest-value engagement categories healthcare publishers own. Physicians have a professional obligation to complete CME hours. When that obligation drives them to a publisher's site, it produces session depth, repeat visits, and sponsorship opportunity that outperforms almost any other traffic category.
That dynamic is now structurally threatened.
When a clinician asks an AI assistant a clinical question: about a treatment protocol, a drug interaction, a therapeutic area update they receive a synthesised answer. That answer is frequently built on the publisher's content. But the interaction happens on the AI platform. The CME credit is earned somewhere else. The sponsored recommendation surfaces in someone else's environment. The physician leaves satisfied without ever visiting the original publisher.
CME revenue declines not because physicians are less engaged with clinical education, but because the engagement is increasingly happening in interfaces the publisher does not own or monetise. As that migration accelerates, the downstream effects compound: sponsorship pipelines thin because HCP attention is harder to demonstrate and attribute, session depth metrics weaken, and the case for direct publisher partnerships with pharmaceutical brands becomes harder to make.
Why One Leak Makes the Other Worse
Both problems reduce the publisher's ability to demonstrate trustworthy HCP reach to advertisers. Bot-distorted inventory makes the engagement data unreliable. CME migration off-platform reduces the genuine engagement the publisher can point to. Together, they create a situation where the actual HCP audience which is real and valuable becomes harder to prove and harder to monetise.
Healthcare publishers are reporting 15–29% year-on-year revenue decline as AI search and AI content consumption grow. That headline number is made up of many individual factors, but these two leaks are structural contributors that are unlikely to self-correct.
The Fix
The response to both problems requires the same underlying move: bringing the AI experience back inside the publisher's ecosystem, and establishing clear ownership over how content is accessed commercially.
Publishers who keep HCP engagement on their own domain through AI experiences that run on their content, their infrastructure, and their domain retain the attribution chain that makes their audience valuable to pharmaceutical and life sciences advertisers. Publishers who establish licensing frameworks around their content convert what is currently being extracted for free into a structured, recurring revenue stream.
This is not a future-state aspiration. The infrastructure to do both exists now.
Publisher AI Suite by Admanager was built specifically for this. Site-Specific LLM keeps clinical AI interactions inside the publisher's ecosystem. AI Ads opens a new premium inventory category across the AI chat screen monetized on HCP engagement rather than bot-distorted open-web impressions. The Licensed Content Marketplace puts enforceable smart contracts around content that is currently being scraped without compensation.
The publishers who close these leaks in 2026 will not just protect existing revenue. They will build the kind of demonstrable HCP reach that the market is increasingly willing to pay a premium for.
See how Publisher AI Suite works: request a demo here.